Spinraza denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for spinraza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Spinraza as Experimental

Spinraza (nusinersen) received FDA approval for spinal muscular atrophy (SMA). However, Aetna's coverage policies sometimes apply an "experimental or investigational" denial when the specific patient population, SMA type, or clinical context falls outside the exact parameters Aetna's Clinical Policy Bulletin recognizes as established. This most commonly arises for adult SMA patients, patients with atypical presentations, or off-label uses not explicitly listed in Aetna's policy.

It is critical to understand: an FDA approval does not automatically guarantee coverage under a specific insurer's policy. Conversely, an insurer labeling a treatment "experimental" does not mean the treatment lacks scientific support — it means your appeal must demonstrate that the specific use is medically appropriate and consistent with accepted medical practice.

## Federal Appeal Rights

• ACA §2719 external review: For non-grandfathered plans, you have the right to independent external review of an experimental-or-investigational denial. This right is specifically preserved under the ACA for this denial category. The window is typically approximately four months from denial.
• ERISA §503: Employer-plan members are entitled to the full internal appeal process and access to the specific policy language and evidence Aetna relied upon.
• Expedited review: SMA is a progressive neuromuscular disease. If clinical deterioration is occurring, request expedited appeal on the basis of urgent medical need.

## Documentation to Gather

• Diagnosis and SMA type confirmation: Genetic testing results; neuromuscular specialist's diagnosis with documentation of SMA type and functional classification.
• FDA approval documentation: A copy of the FDA-approved prescribing information for Spinraza, which confirms its approved indication.
• Professional society guidelines: A reference (not a citation with statistics) to the relevant neuromuscular specialty organization's guidance supporting use in this patient's clinical situation.
• Treating specialist letter: A letter from a neuromuscular specialist or neurologist addressing Aetna's experimental characterization directly — citing the clinical basis for use and the patient's specific medical circumstances.
• Functional status documentation: Chart notes quantifying the patient's current motor, respiratory, and nutritional status, and the clinical consequences of treatment delay.

## Criteria-Mapping Framework

Request Aetna's Clinical Policy Bulletin for Spinraza. Identify the populations or uses Aetna recognizes as non-experimental and map your patient's situation to those criteria:

| Aetna Recognition Criterion | Patient-Specific Evidence | |---|---| | FDA-approved indication for SMA | FDA label (attached); diagnosis confirmation | | Patient meets covered population criteria | Genetic report + specialist notes | | Standard of care per applicable guidelines | Specialist letter referencing professional society guidance |

If Aetna's policy does not cover your patient's specific SMA subtype at all, your appeal should argue that the exclusion is inconsistent with the medical standard of care and request that the IRO reviewer apply an independent clinical standard.